Nelfinavir mesylate is under clinical development by Pfizer and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Nelfinavir mesylate’s likelihood of approval (LoA) and phase transition for Multiple Myeloma (Kahler Disease) took place on 11 Jul 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
In addition, the same event on 11 Jul 2022 decreased Nelfinavir mesylate’s LoA and PTSR for Refractory Multiple Myeloma, and decreased LoA and PTSR for Relapsed Multiple Myeloma.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nelfinavir mesylate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Nelfinavir mesylate overview
Nelfinavir Mesylate (Viracept) belongs to the class of protease inhibitors, acts as an antiretroviral drug . It is formulated as tablets, film coated tablets and powder for oral route of administration. It is indicated in antiretroviral combination treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children of 3 years of age and older. The drug candidate is under development for the treatment of multiple myeloma.
Nelfinavir Mesylate is under development for the treatment of relpased or refractory multiple myeloma in the U.S. It was also under development for acute myelocytic leukemia, acute lymphocytic leukemia, diffuse large b-cell lymphoma, hodgkin lymphoma, mantle cell lymphoma, natural killer cell lymphomas, follicular lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphomas, cutaneous T-cell lymphoma, lymphoproliferative disorders, sezary syndrome, mycosis fungoides, T-cell leukemia, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, aggressive NK-cell leukemia, extranodal NK/T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, primary cutaneous T-cell lymphoma and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Quick View Nelfinavir mesylate LOA Data
|Highest Development Stage|